News & Press

CordenPharma COVID-19 Customer Letter

April 6, 2020
COVID-19 > Read CEO Dr. Micheal Quirmbach's Customer Letter Response to COVID-19.

CordenPharma’s Weekly Update to COVID-19 (Novel Coronavirus)
Please Read CEO & President Dr. Michael Quirmbach’s Letter to Customers

 
Please click here to inform us of any urgent questions or concerns regarding COVID-19


Dear Valued Customer,

Due to the unfortunate progression of COVID-19 (Novel Coronavirus) infections taking place globally, I have instructed all CordenPharma employees and manufacturing facilities to cease and cancel all business travel and face-to-face meetings through the end of April, and to convert all scheduled meetings into video or teleconference calls.

In addition, CordenPharma’s Corporate Compliance Team has instructed our global network of facilities to reschedule all customer-related quality audits originally scheduled in Q2 of 2020, to take place in the second half of 2020. The local site compliance representatives will reach out to rearrange the audits. Obviously, we will accommodate any regulatory agency audit requests that may arise during this period.

On April 3rd, we were informed that our CordenPharma Plankstadt facility in Germany has experienced their first confirmed COVID-19 case. As a result, we immediately quarantined the staff that were in contact with the employee, and have shut down our development production area where the employee was located. I would like to emphasize that this shut down only impacts this particular part of our development area, and that the routine bulk manufacturing and packaging areas continue to be operational with minimal delays. All impacted customers will be contacted immediately by their Key Account Manager and / or Site Project Manager.

I had previously communicated that our facility CordenPharma Bergamo had made the decision to halt routine manufacturing for one week (Thursday, March 26th through Wednesday, April 1st).  I am happy to announce that the site has resumed routine manufacturing on schedule, according to plan.

All our other manufacturing facilities in Italy, France, Switzerland, Belgium and the United States remain fully operational, and have not experienced any significant disruption arising from issues related to COVID-19.

CordenPharma employees, from the Executive Leadership Team to the Marketing & Sales Team, Facility Managing Directors and Operators, are aligned and committed to mitigating any impact on delivering your critical, often lifesaving, medications. We are doing everything possible on our end to support your patients through this crisis.

We appreciate your patience as we react to this global issue, and thank you for your ongoing support in returning to “business as usual” as quickly as possible. Feel free to reach out to your Key Account Managers or fill out this form with any questions or concerns.

I wish you and your families stay safe & healthy, as we continue to work together as a collective community to support business continuity and each other.

Best Regards,

Dr. Michael Quirmbach
Chief Executive Officer & President
CordenPharma